Feline Infectious Peritonitis mRNA Vaccine Elicits Both Humoral and Cellular Immune Responses in Mice

Terza Brostoff,Hannah P. Savage,Kenneth A. Jackson,Joseph C. Dutra,Justin H. Fontaine,Dennis J. Hartigan-O'Connor,Randy P. Carney,Patricia A. Pesavento

DOI: https://doi.org/10.3390/vaccines12070705

2024-06-25

Vaccines

Abstract:Feline infectious peritonitis (FIP) is a devastating and often fatal disease caused by feline coronavirus (FCoV). Currently, there is no widely used vaccine for FIP, and many attempts using a variety of platforms have been largely unsuccessful due to the disease's highly complicated pathogenesis. One such complication is antibody-dependent enhancement (ADE) seen in FIP, which occurs when sub-neutralizing antibody responses to viral surface proteins paradoxically enhance disease. A novel vaccine strategy is presented here that can overcome the risk of ADE by instead using a lipid nanoparticle-encapsulated mRNA encoding the transcript for the internal structural nucleocapsid (N) FCoV protein. Both wild type and, by introduction of silent mutations, GC content-optimized mRNA vaccines targeting N were developed. mRNA durability in vitro was characterized by quantitative reverse-transcriptase PCR and protein expression by immunofluorescence assay for one week after transfection of cultured feline cells. Both mRNA durability and protein production in vitro were improved with the GC-optimized construct as compared to wild type. Immune responses were assayed by looking at N-specific humoral (by ELISA) and stimulated cytotoxic T cell (by flow cytometry) responses in a proof-of-concept mouse vaccination study. These data together demonstrate that an LNP–mRNA FIP vaccine targeting FCoV N is stable in vitro, capable of eliciting an immune response in mice, and provides justification for beginning safety and efficacy trials in cats.

immunology,medicine, research & experimental

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop an effective vaccine to prevent Feline Infectious Peritonitis (FIP). FIP is a fatal disease caused by Feline Coronavirus (FCoV), and there is currently no widely - used vaccine. Most previous vaccine attempts have failed mainly due to the following reasons:

1. **Complex pathological mechanism**: The pathogenesis of FIP is very complex, which makes vaccine development difficult.
2. **Antibody - dependent enhancement (ADE)**: The antibody responses induced by some vaccines can actually worsen the disease. This is because non - neutralizing or sub - neutralizing antibodies bind to the viral surface proteins and then mediate the virus to enter monocytes and macrophages through Fc receptors, thus exacerbating the disease.

To overcome these problems, the research team proposed a new vaccine strategy, that is, using a lipid nanoparticle (LNP) - encapsulated mRNA vaccine encoding the internal structural nucleocapsid (N) protein of FCoV. This strategy aims to avoid the ADE problems that may be caused by targeting viral surface proteins (such as S protein), and the N protein is highly conserved in both serotypes, so it may provide broader protection.

Specifically, the research team developed two mRNA vaccines:
- Wild Type (WT) mRNA
- mRNA with optimized GC content

These mRNA vaccines have shown good stability and immunogenicity in vitro and in preliminary in vivo experiments, and can induce mice to produce specific humoral immunity (detected by ELISA) and cellular immune responses (detected by flow cytometry for cytotoxic T - cell responses). These results provide a basis for the next safety and efficacy trials in cats.

### Key formulas and terms

- **Antibody - dependent enhancement (ADE)**: \[ \text{ADE}=\frac{\text{Enhanced infection rate}}{\text{Normal infection rate}} \]
- **mRNA stability**: The persistence of mRNA in cells is measured by quantitative reverse - transcription PCR (q - RT PCR).
- **Protein expression**: The ability of mRNA to be translated into N protein is evaluated by immunofluorescence assay (IFA) and Western Blot.

### Summary

The main goal of this study is to develop an FIP vaccine based on mRNA technology, which can effectively induce humoral and cellular immune responses while avoiding the ADE problems that may be caused by traditional vaccines. The research results show that the mRNA vaccine with optimized GC content exhibits better stability and immunogenicity in vitro and in the mouse model, laying a foundation for further pre - clinical studies.